Impact of recovery on fraction unbound using equilibrium dialysis
- PMID: 22161810
- DOI: 10.1002/jps.23013
Impact of recovery on fraction unbound using equilibrium dialysis
Abstract
Historically, recovery had been used to evaluate the data quality of plasma protein binding or tissue binding obtained from equilibrium dialysis assays. Low recovery was often indicative of high nonspecific binding, instability, or low solubility. This study showed that, when equilibrium was fully established in the dialysis assay, low recovery due to nonspecific binding had no impact on the determination of fraction unbound. The conclusion was supported by the principles of the equilibrium dialysis assay, experimental data, and mathematic simulations. The results suggested that the use of recovery as an acceptance criterion for the equilibrium dialysis assay in drug discovery was too restrictive, and introduced the additional burden of repeating studies unnecessarily.
Copyright © 2011 Wiley Periodicals, Inc.
Similar articles
-
Studies of drug binding to plasma proteins using a variant of equilibrium dialysis.J Pharm Biomed Anal. 2005 Jul 1;38(3):381-9. doi: 10.1016/j.jpba.2005.01.015. Epub 2005 Feb 24. J Pharm Biomed Anal. 2005. PMID: 15925237
-
Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs.J Pharm Sci. 2011 Jun;100(6):2498-507. doi: 10.1002/jps.22452. Epub 2011 Jan 6. J Pharm Sci. 2011. PMID: 21213309
-
Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding.J Lab Autom. 2011 Feb;16(1):56-67. doi: 10.1016/j.jala.2010.06.002. Epub 2011 Jan 12. J Lab Autom. 2011. PMID: 21609686
-
The bioanalytical challenge of determining unbound concentration and protein binding for drugs.Bioanalysis. 2013 Dec;5(24):3033-50. doi: 10.4155/bio.13.274. Bioanalysis. 2013. PMID: 24320129 Review.
-
Measurement and analysis of unbound drug concentrations.Clin Pharmacokinet. 1996 Jun;30(6):445-62. doi: 10.2165/00003088-199630060-00003. Clin Pharmacokinet. 1996. PMID: 8792057 Review.
Cited by
-
Development and validation of a sensitive method to quantify a poorly ionized drug, pocapavir, in C57BL/6 mouse plasma.Bioanalysis. 2025 Mar;17(6):393-398. doi: 10.1080/17576180.2025.2480533. Epub 2025 Mar 21. Bioanalysis. 2025. PMID: 40118813
-
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.Sci Transl Med. 2024 Mar 13;16(738):eadi0979. doi: 10.1126/scitranslmed.adi0979. Epub 2024 Mar 13. Sci Transl Med. 2024. PMID: 38478629 Free PMC article.
-
Heterogeneous drug tissue binding in brain regions of rats, Alzheimer's patients and controls: impact on translational drug development.Sci Rep. 2019 Mar 29;9(1):5308. doi: 10.1038/s41598-019-41828-4. Sci Rep. 2019. PMID: 30926941 Free PMC article.
-
10-DEBC Hydrochloride as a Promising New Agent against Infection of Mycobacterium abscessus.Int J Mol Sci. 2022 Jan 6;23(2):591. doi: 10.3390/ijms23020591. Int J Mol Sci. 2022. PMID: 35054777 Free PMC article.
-
Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.Leukemia. 2019 Jul;33(7):1663-1674. doi: 10.1038/s41375-018-0364-x. Epub 2019 Jan 30. Leukemia. 2019. PMID: 30700841 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical